FDMT — 4D Molecular Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $439.55m
- $36.90m
- $85.21m
Annual income statement for 4D Molecular Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 18 | 3.13 | 20.7 | 0.037 | 85.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 89.4 | 113 | 134 | 188 | 245 |
| Operating Profit | -71.3 | -110 | -113 | -188 | -160 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -71.3 | -107 | -101 | -161 | -140 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -71.3 | -107 | -101 | -161 | -140 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -71.3 | -107 | -101 | -161 | -140 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -71.3 | -107 | -101 | -161 | -140 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.57 | -3.32 | -2.58 | -2.98 | -2.42 |